Navigation Links
Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
Date:9/14/2009

TARRYTOWN, N.Y., Sept. 14 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced the completion of patient enrollment in two randomized, double-masked, Phase 3 clinical trials evaluating VEGF Trap-Eye in the treatment of the neovascular form of age-related macular degeneration (wet AMD). In each study of the VIEW (VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD) program, VEGF Trap-Eye is being evaluated for its effect on maintaining and improving vision when dosed as an intravitreal injection on a schedule of 0.5 milligram (mg) every four weeks, 2.0 mg every four weeks, or 2.0 mg every eight weeks (following three monthly doses), as compared with intravitreal ranibizumab (Lucentis((R)), a registered trademark of Genentech, Inc.) administered 0.5 mg every four weeks during the first year of the studies. As-needed (PRN) dosing with both agents is being evaluated during the second year of each study. These studies are part of the global development program for VEGF Trap-Eye being conducted by Regeneron and Bayer HealthCare AG. Each study has enrolled in excess of the targeted 1,200 patient goal. One-year primary endpoint data from both studies are expected in the fourth quarter of 2010.

VEGF Trap-Eye, an investigational drug, is being developed by Regeneron and Bayer HealthCare AG for the potential treatment of eye diseases, including wet AMD, diabetic macular edema (DME), and Central Retinal Vein Occlusion (CRVO). Regeneron maintains exclusive rights to VEGF Trap-Eye in the United States. Bayer HealthCare has exclusive rights to market VEGF Trap-Eye outside the United States, where the companies will share equally in profits from any future sales of VEGF Trap-Eye.

"Even with recent advances in the treatment of wet
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021
2. Roskamp Institute Announces Enrollment of First Students to Participate in its Innovative Research Doctorate Program
3. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
4. Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial
5. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
6. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
7. TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
8. InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients
9. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
10. Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study
11. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... that address unmet medical needs in the areas ... on December 24, 2014 it closed its previously ... raised approximately $2.3 million in gross proceeds from ... proceeds from the offering to fund its research ...
(Date:12/24/2014)... LONDON , December 24, 2014 ... grow at an average rate of 8.1%. The US ... Hip, knee and spine surgeries are the common orthopedic ... they have a lower penetration. Increased number of product ... composites. Non-metallic orthopedic devices have gained popularity in the ...
(Date:12/24/2014)... LifeScienceIndustryResearch.com adds 2014 ... Industry of 178 pages providing 10 company ... The 2014 Market Research Report ... professional and deep research report on Global ... report introduces Disposable Syringe basic information including ...
Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5
... 500th sale of its ExacTrac® patient positioning ... physicians continued focus on adopting clinically proven systems for ... access to advanced radiation therapy for patients. ... decade ago, has been proven consistent and reliable in ...
... FRANCISCO, Jan. 16, 2012 Dicom Systems ( http://www.dcmsys.com ... pleased to announce their selection as the Vendor Neutral ... full service physician-owned teleradiology group. Dicom ... have the capacity to turn your current storage to ...
Cached Medicine Technology:Brainlab ExacTrac® System Achieves Major Sales Milestone 2ONRAD, Inc. Chooses Dicom Systems' Vendor Neutral Archive 2
(Date:12/24/2014)... News) -- The holidays can be a challenge for people ... foods and drinks. "This is the season in which ... migraine," Dr. David Dodick, chair of the American Migraine Foundation, ... important to think through food and beverage choices, to help ... a professor of neurology at the Mayo Clinic in Scottsdale, ...
(Date:12/24/2014)... (HealthDay News) -- A new, injectable weight-loss drug has ... The agency on Tuesday approved Saxenda (liraglutide) for ... overweight and have at least one weight-related health condition, ... high cholesterol. Patients taking the drug, made by ... exercise regularly, the FDA noted. "Obesity is a ...
(Date:12/24/2014)... Researchers say they have used human embryonic stem cells ... While this had already been done using rodent ... types of cells -- called primordial germ cells -- ... to the team at the University of Cambridge in ... one of the earliest events during early mammalian development," ...
(Date:12/24/2014)... 24, 2014 (HealthDay News) -- A lab technician with ... have been exposed to the Ebola virus in an ... up to a dozen other lab workers are being ... afternoon. The possible exposure occurred Monday when CDC ... of the potentially lethal virus to another CDC lab ...
(Date:12/24/2014)... 2014 Gluten, a protein found predominately ... have an intolerance to gluten, causing side effects that ... headaches, joint pain and fatigue. For this reason, Diet ... that deliver safe and fast weight loss while teaching ... gluten allergy reaction. These gluten free diet plans combine ...
Breaking Medicine News(10 mins):Health News:Expert Offers Tips for Preventing Holiday Migraines 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:CDC Monitors Lab Worker for Possible Ebola Exposure 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3
... outstanding growth, and success in navigating troubled economy. , ... ... [Jackson Healthcare] (JH) has been named to Inc. magazine,s second annual ... most entrepreneurial private companies. Jackson Healthcare is ranked 40th on ...
... Patient Safety,Technologies, Inc. (PST) (OTC Bulletin Board: PSTX) ... equity financing in a first closing of a,private placement. ... at its SurgiCount Medical subsidiary. Investors in the first,closing ... common stock at a price of $1.25 per share ...
... SOUTH SAN FRANCISCO, Calif., Aug. 27 VaxGen,Inc. ... a financial and operational update since the filing ... Securities and Exchange Commission,on August 14, 2008., ... $59 million in cash and equivalents and,investment securities ...
... preterm birth cuts risk in half, study finds , , WEDNESDAY, ... at risk of preterm delivery, cut the rate of cerebral ... found. , "If deemed to be at high or immediate ... doctors should consider using magnesium sulfate to prevent their child ...
... COLUMBUS, Ga., Aug. 27 Aflac Incorporated,(NYSE: AFL ... at the Keefe,Bruyette & Woods 2008 Insurance Conference. President ... Incorporated, and he is,scheduled to make a presentation on ... Incorporated presentation, Mr. Cloninger will discuss the,company,s outlook for ...
... Preparedness Event to be held on September 8, 2008, ... Adult Center in Burbank will be hosting a Disaster Preparedness,Event ... City of Burbank. The focus of this event is to ... to look after yourself in an emergency.,Participants will learn how ...
Cached Medicine News:Health News:Jackson Healthcare Ranked 48th of All Health Companies on Inc. Magazine's 2008 List of 5000 Fastest Growing Private Companies 2Health News:Patient Safety Technologies Closes on $2.325 Million in Equity Financing 2Health News:VaxGen Provides Financial Update Following the Filing of Its 10-Q for Second Quarter With SEC; Results Include $8.5 Million Charge in Respect of Manufacturing Plant Asset Impairment 2Health News:VaxGen Provides Financial Update Following the Filing of Its 10-Q for Second Quarter With SEC; Results Include $8.5 Million Charge in Respect of Manufacturing Plant Asset Impairment 3Health News:Magnesium Sulfate Reduces Threat of Cerebral Palsy 2Health News:Magnesium Sulfate Reduces Threat of Cerebral Palsy 3Health News:Aflac Incorporated To Present at the Keefe, Bruyette & Woods 2008 Insurance Conference 2
... Upper extremity fixator has been designed to ... by allowing independent movement of its clamp ... goals has been to reduce complexity of ... ease of use. The Hoffmann® II Compact™ ...
Provides basic reduction capabilities for angulation, rotation and length. Ball joint design offers fracture reduction in all planes....
... System for distal radius fractures allows incremental ... and rotation. The unique wrist lock enables ... extension without losing fracture reduction. Post-op adjustments ... surgeons office. Priced competitively and sold in ...
... The Universal Mini External ... hold using smooth, thin diameter ... 2.5 mm). This hold ... frame which stabilizes fractures and ...
Medicine Products: